EU/3/16/1666: Orphan designation for the treatment of graft-versus-host disease

Rimiducid

Overview

On 30 May 2016, orphan designation (EU/3/16/1666) was granted by the European Commission to QRC Consultants Ltd., United Kingdom, for rimiducid (AP1903) for the treatment of graft-versus-host disease.

The sponsorship was transferred to Bellicum Pharma Limited, United Kingdom, in May 2017.

The sponsorship was transferred to Bellicum Pharma GmbH, Germany, in February 2019.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in April 2022 on request of the Sponsor.

Key facts

Active substance
Rimiducid
Intended use
Treatment of graft-versus-host disease
Orphan designation status
Withdrawn
EU designation number
EU/3/16/1666
Date of designation
30/05/2016
Sponsor

Bellicum Pharma GmbH
Josephspitalstrasse 15
Altstadt-Lehel
80331 Munich
Bavaria
Germany
Tel. +49  1721448300
E-mail: jlamport@bellicum.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating